Pluristem closes enrolment for Phase II trial of PLX-PAD cells to treat intermittent claudication

Israeli-based drug development company Pluristem Therapeutics has closed enrolment for its Phase II trial of placental expanded (PLX-PAD) cells to treat intermittent claudication (IC), a peripheral artery disease (PAD).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news